Mesoblast (ASX:MSB) share price could be facing more pressure in 2021

The Mesoblast limited (ASX: MSB) share price could come under further pressure this year on rumours that it needs a capital injection.

The MSB share price fell 1.3% ahead of the close to $2.23 when the S&P/ASX 200 Index (Index:^AXJO) rallied 0.5%.

Shares in the biotech have been on the nose over the past few months and this won’t be a good time to go cap in hand to shareholders.

$100m cap raise cloud hanging over Mesoblast

But that’s exactly what broking firm CLSA is warning is likely to happen as Mesoblast needs to cover a close to $100 million cash shortfall, reported the Australian Financial Review.

CLSA’s analyst Hashan De Silva believes that Mesoblast will need to start repaying a US$75 million loan with Hercules Capital…